Early Treatment with Hydroxychloroquine and Azithromycin: A Real-Life Monocentric Retrospective Cohort Study of 30,423 COVID-19 Patients
et al., medRxiv, doi:10.1101/2023.04.03.23287649 (Preprint)
, Early Treatment with Hydroxychloroquine and Azithromycin: A Real-Life Monocentric Retrospective Cohort Study.., medRxiv, doi:10.1101/2023.04.03.23287649 (Preprint)
Retrospective 30,423 patients in France, showing very low mortality overall for outpatients treated with HCQ+AZ and for patients <50, and significantly lower mortality with HCQ and HCQ+AZ versus other treatments. Efficacy was greater for outpatients vs. inpatients.
|
risk of death, 59.0% lower, OR 0.41, p = 0.008, HCQ, outpatients, RR approximated with OR.
|
|
risk of death, 71.0% lower, OR 0.29, p < 0.001, HCQ+AZ, outpatients, RR approximated with OR.
|
|
risk of death, 41.0% lower, OR 0.59, p < 0.001, HCQ, inpatients, RR approximated with OR.
|
|
risk of death, 45.0% lower, OR 0.55, p < 0.001, HCQ+AZ, inpatients, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Million et al., 4 Apr 2023, retrospective, France, preprint, 17 authors, study period 2 March, 2020 - 31 December, 2021.
Contact:
matthieumillion@gmail.com.
Early Treatment with Hydroxychloroquine and Azithromycin: A Real-Life Monocentric Retrospective Cohort Study of 30,423 COVID-19 Patients
doi:10.1101/2023.04.03.23287649
Objective To estimate the comparative effectiveness of combination therapy with hydroxychloroquine (HCQ) and azithromycin for coronavirus disease 2019 (COVID-19)related death based on a large monocentric cohort independent of investigators' putative biases in a real-world setting. Design Retrospective monocentric cohort study, with comprehensive data collection authenticated by an external bailiff and death reports from a national database (French National Death Registry).
Conflicts of interest All authors have completed the Unified Competing Interest form (available on request from the corresponding author). DR declare grants or contracts and royalties or licenses from Hitachi High-Technologies Corporation, Tokyo, Japan. DR is scientific board member of Eurofins company. DR is founder and shareholder of a microbial culture company (Culture Top), two biotechnology companies (Techno-jouvence, and Gene and Green TK), and a rapid diagnosis of infectious diseases company (Pocramé). All authors declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. Our group used widely available generic drugs distributed by many pharmaceutical companies.
Details of contributors .
References
Aherfi, Pradines, Devaux, Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV, Future Microbiol, doi:10.2217/fmb-2021-0019
Amrane, Tissot-Dupont, Doudier, Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, -January 31st to March 1st, 2020: A respiratory virus snapshot, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101632
Anderson, Bijlmer, Fournier, Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group, MMWR Recomm Rep
Andreani, Bideau, Duflot, In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microb Pathog, doi:10.1016/j.micpath.2020.104228
Anglemyer, Horvath, Bero, Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials, Cochrane Database Syst Rev, doi:10.1002/14651858.MR000034.pub2
Blonde, Khunti, Harris, Meizinger, Skolnik, Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician, Adv Ther, doi:10.1007/s12325-018-0805-y
Boschi, Bideau, Andreani, Heterogeneity in susceptibility to hydroxychloroquine of SARS-CoV-2 isolates, Front Biosci (Landmark Ed), doi:10.52586/5043
Boulware, Pullen, Bangdiwala, A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19, N Engl J Med, doi:10.1056/NEJMoa2016638
Brouqui, Lagier, Parola, Viral clearance in patients with COVID-19: associated factors and the role of antiviral treatment, Authorea, doi:10.22541/au.167948825.59270994/v1
Cavalcanti, Zampieri, Rosa, Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19, N Engl J Med, doi:10.1056/NEJMoa2019014
Chen, Zhang, Fu, Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study, medRxiv, doi:.org/10.1101/2020.06.19.20136093
Colson, Fournier, Chaudet, Analysis of SARS-CoV-2 Variants From 24,181 Patients Exemplifies the Role of Globalization and Zoonosis in Pandemics, Front Microbiol, doi:10.3389/fmicb.2021.786233
Corrigan-Curay, Sacks, Woodcock, Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness, JAMA, doi:10.1001/jama.2018.10136
Craig, Cooper, Gunnell, Using natural experiments to evaluate population health interventions: new Medical Research Council guidance, J Epidemiol Community Health, doi:10.1136/jech-2011-200375
Curfman, Morrissey, Drazen, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, N Engl J Med, doi:10.1056/NEJMe058314
Doshi, Godlee, Abbasi, Covid-19 vaccines and treatments: we must have raw data, now, BMJ, doi:10.1136/bmj.o102
Dubee, Roy, Vielle, Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial, Clin Microbiol Infect, doi:10.1016/j.cmi.2021.03.005
Fournier, Houhamdi, Colson, SARS-CoV-2 Vaccination and Protection Against Clinical Disease: A Retrospective Study, Bouches-du-Rhone District, Southern France, Front Microbiol, doi:10.3389/fmicb.2021.796807
Gautret, Colson, Chaudet, Raoult, Evaluation of Strategies to Fight COVID-19: The French Paradigm, J Clin Med, doi:10.3390/jcm10132942
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Gautret, Million, Jarrot, Natural history of COVID-19 and therapeutic options, Expert Rev Clin Immunol, doi:10.1080/1744666X.2021.1847640
Gendrot, Andreani, Boxberger, Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101873
Godlee, Covid-19: The lost lessons of Tamiflu, BMJ, doi:10.1136/bmj.m4701
Godlee, Open letter to Roche about oseltamivir trial data, BMJ
Gordon, Hiatt, Bouhaddou, Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms, Science, doi:10.1126/science.abe9403
Gordon, Jang, Bouhaddou, A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature, doi:10.1038/s41586-020-2286-9
Gysi, Valle, Zitnik, Network medicine framework for identifying drug-repurposing opportunities for COVID-19, Proc Natl Acad Sci U S A, doi:10.1073/pnas.2025581118
Hammond, Leister-Tebbe, Gardner, Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2118542
Hill, The Environment and Disease: Association or Causation ?, Proc Royal Soc Med
Hong, Jang, Hur, Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication, Infect Chemother, doi:10.3947/ic.2020.52.3.396
Huang, Li, Xiao, Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19
Kamran, Moeed, Mirza, Clearing the Fog: Is Hydroxychloroquine Effective in Reducing Coronavirus Disease-2019 Progression? A Randomized Controlled Trial, Cureus, doi:10.7759/cureus.14186
Kartsonaki, Baillie, Barrio, Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19, Int J Epidemiol, doi:.org/10.1093/ije/dyad012
Kerridge, Lowe, Henry, Ethics and evidence based medicine, BMJ, doi:10.1136/bmj.316.7138.1151
Khullar, Jena, Natural Experiments" in Health Care Research, JAMA Health Forum, doi:10.1001/jamahealthforum.2021.0290
Lagier, Colson, Dupont, Testing the repatriated for SARS-Cov2: Should laboratory-based quarantine replace traditional quarantine?, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101624
Lagier, Million, Cortaredona, Outcomes of
Lagier, Million, Gautret, Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101791
Lagier, Raoult, Deadly infectious diseases such as Ebola: the parachute paradigm, Clin Microbiol Infect, doi:10.1016/j.cmi.2015.02.027
Lim, Hippchen, Unger, An Outpatient Management Strategy Using a Coronataxi Digital Early Warning System Reduces Coronavirus Disease 2019 Mortality, Open Forum Infect Dis, doi:10.1093/ofid/ofac063
Liu, Cao, Xu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, doi:10.1038/s41421-020-0156-0
Long, Wu, Chen, Effect of early oxygen therapy and antiviral treatment on disease progression in patients with COVID-19: A retrospective study of medical charts in China, PLoS Negl Trop Dis, doi:10.1371/journal.pntd.0009051
Medical, World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects, JAMA, doi:10.1001/jama.2013.281053
Mehra, Desai, Ruschitzka, Patel, RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
Million, Chabriere, Cortaredona, Predictive factors of clinical assays on hydroxychloroquine for COVID-19 mortality during the first year of the pandemic: a metasynthesis, Afr J Clin Exper Microbiol, doi:10.4314/ajcem.v23i1.1
Million, Gautret, Colson, Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world, New Microbes New Infect, doi:10.1016/j.nmni.2020.100709
Million, Lagier, Gautret, Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101738
Million, Lagier, Hourdain, Cardiovascular Safety of Hydroxychloroquine-Azithromycin in 424 COVID-19 patients, doi:10.20944/preprints202303.0325.v1
Million, Lagier, Tissot-Dupont, Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients, Rev Cardiovasc Med, doi:10.31083/j.rcm2203116
Million, Thuny, Richet, Raoult, Long-term outcome of Q fever endocarditis: a 26-year personal survey, Lancet Infect Dis, doi:10.1016/S1473-3099(10)70135-3
Nyberg, Ferguson, Nash, Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron, Lancet, doi:10.1016/S0140-6736(22)00462-7
Onder, Rezza, Brusaferro, Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy, JAMA, doi:10.1001/jama.2020.4683
Perinel, Launay, Botelho-Nevers, Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients, Clin Infect Dis, doi:10.1093/cid/ciaa394
Rajter, Sherman, Fatteh, Vogel, Sacks et al., ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19, medRxiv, doi:10.1101/2020.06.06.20124461
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study, Chest, doi:10.1016/j.chest.2020.10.009
Rosengren, Soderberg, Lundberg, COVID-19 in people aged
Roussel, Raoult, Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences, New Microbes New Infect, doi:10.1016/j.nmni.2020.100710
Scola, Bideau, Andreani, Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards, Eur J Clin Microbiol Infect Dis, doi:10.1007/s10096-020-03913-9
Smith, Pell, Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials, BMJ, doi:10.1136/bmj.327.7429.1459
Su, Ling, Ma, Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China, Biosci Trends, doi:10.5582/bst.2020.03340
Touret, Gilles, Barral, In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, Sci Rep, doi:10.1038/s41598-020-70143-6
Vincent, Bergeron, Benjannet, Chloroquine is a potent inhibitor of SARS coronavirus infection and spread, Virol J, doi:10.1186/1743-422X-2-69
Von Elm, Altman, Egger, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, Lancet, doi:10.1016/S0140-6736(07)61602-X
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Who, Coronavirus disease (COVID-19): Solidarity Trial and hydroxychloroquine
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.